Third-quarter results for the fiscal year ending December 2026
SymBio Pharmaceuticals Limited Group (the filing company and its consolidated subsidiaries)
TREAKISYM® intravenous infusion 100 mg/4 mL [RTD formulation], brincidofovir (BCV), IVD business
Revenue declined due to the drug price revision and the penetration of generic products, while research and development expenses increased as research and development activities for a global Phase III clinical trial targeting adenovirus infections after hematopoietic stem cell transplantation moved into full-scale operation. The main reason the projected full-year net loss has been exceeded is that partnering revenue expected to be recognized for the full year has not yet been recorded.
Revenue: ¥722,099 thousand (down 25.6% year on year); operating loss: ¥4,870,788 thousand; ordinary loss: ¥4,849,508 thousand; quarterly net loss attributable to owners of the parent: ¥4,879,997 thousand; net assets: negative ¥1,295,695 thousand; equity ratio: negative 165.1%. An impairment loss of ¥16,282 thousand was recorded as an extraordinary loss.
Cumulative third-quarter period of the fiscal year ending December 2026 (1 January 2026 to 30 September 2026)
No change from the consolidated earnings forecast announced on 5 February 2026. The full-year forecast is revenue of ¥3,891 million, an operating loss of ¥4,231 million, an ordinary loss of ¥4,291 million, and a net loss attributable to owners of the parent of ¥4,331 million.
Company response
Development of the Phase II clinical trial targeting cytomegalovirus infection has been temporarily halted. Development of the international joint Phase Ib clinical trial targeting patients with malignant lymphoma has been temporarily suspended.
The Company will advance the Phase III and Phase II clinical trials for BCV, development toward the filing of a new drug application and commercialization, preservation of its intellectual property base, early commercialization of the IVD business, funding including equity financing, partnering with other companies, cost reductions, and a review of payment terms. The timing of eliminating the negative net assets remains undetermined.
| Item | Details |
|---|---|
| Event name | Third-quarter results for the fiscal year ending December 2026 |
| Date of occurrence | 30 September 2026 (end of the third-quarter consolidated accounting period) |
| Date recognized / date notice received | 29 October 2026 (date of disclosure of the earnings report) |
| Subject Entity | SymBio Pharmaceuticals Limited Group (the filing company and its consolidated subsidiaries) |
| Target Locations / Products | TREAKISYM® intravenous infusion 100 mg/4 mL [RTD formulation], brincidofovir (BCV), IVD business |
| Cause | Revenue declined due to the drug price revision and the penetration of generic products, while research and development expenses increased as research and development activities for a global Phase III clinical trial targeting adenovirus infections after hematopoietic stem cell transplantation moved into full-scale operation. The main reason the projected full-year net loss has been exceeded is that partnering revenue expected to be recognized for the full year has not yet been recorded. |
| Amount of Impact on Business Performance | Revenue: ¥722,099 thousand (down 25.6% year on year); operating loss: ¥4,870,788 thousand; ordinary loss: ¥4,849,508 thousand; quarterly net loss attributable to owners of the parent: ¥4,879,997 thousand; net assets: negative ¥1,295,695 thousand; equity ratio: negative 165.1%. An impairment loss of ¥16,282 thousand was recorded as an extraordinary loss. |
| Accounting period in which recognized | Cumulative third-quarter period of the fiscal year ending December 2026 (1 January 2026 to 30 September 2026) |
| Impact on Earnings Forecast | No change from the consolidated earnings forecast announced on 5 February 2026. The full-year forecast is revenue of ¥3,891 million, an operating loss of ¥4,231 million, an ordinary loss of ¥4,291 million, and a net loss attributable to owners of the parent of ¥4,331 million. |
| Suspended operations | Development of the Phase II clinical trial targeting cytomegalovirus infection has been temporarily halted. Development of the international joint Phase Ib clinical trial targeting patients with malignant lymphoma has been temporarily suspended. |
| Outlook | The Company will advance the Phase III and Phase II clinical trials for BCV, development toward the filing of a new drug application and commercialization, preservation of its intellectual property base, early commercialization of the IVD business, funding including equity financing, partnering with other companies, cost reductions, and a review of payment terms. The timing of eliminating the negative net assets remains undetermined. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined due to the drug price revision and the penetration of generic products, while research and development expenses increased as the global Phase III clinical trial moved into full-scale operation. The Company also cited the fact that partnering revenue expected to be recognized for the full year has not yet been recorded and that funding has fallen short of the amount initially planned.